Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. FDA Endocrinologic and Metabolic Drugs Advisory Committee determined (by a vote of 10 to 2) that the data supporting the new drug application for ONGLYZA (saxagliptin) for the treatment of adults with type 2 diabetes were sufficient to rule out unacceptable cardiovascular risk relative to comparators in the program.
The details can be read here.
No comments:
Post a Comment